StockSays

AXP−0.12moodBE−0.72moodBAH−0.06moodARLP±5.7%earnings Oct 26RHI+0.59moodFIX−0.24moodSLB+0.67moodBOH±5.9%earnings Oct 26RCBC0.00moodRCIAF+0.15moodALV−0.08moodDEA±6.3%earnings Oct 26AXP−0.12moodBE−0.72moodBAH−0.06moodARLP±5.7%earnings Oct 26RHI+0.59moodFIX−0.24moodSLB+0.67moodBOH±5.9%earnings Oct 26RCBC0.00moodRCIAF+0.15moodALV−0.08moodDEA±6.3%earnings Oct 26

FIX−0.24moodSLB+0.67moodBOH±5.9%earnings Oct 26RCBC0.00moodRCIAF+0.15moodALV−0.08moodDEA±6.3%earnings Oct 26GMAB+0.53moodMBLY−0.62moodDASH−0.33moodHBT±5.5%earnings Oct 26FLG−0.48moodFIX−0.24moodSLB+0.67moodBOH±5.9%earnings Oct 26RCBC0.00moodRCIAF+0.15moodALV−0.08moodDEA±6.3%earnings Oct 26GMAB+0.53moodMBLY−0.62moodDASH−0.33moodHBT±5.5%earnings Oct 26FLG−0.48mood

ALV−0.08moodDEA±6.3%earnings Oct 26GMAB+0.53moodMBLY−0.62moodDASH−0.33moodHBT±5.5%earnings Oct 26FLG−0.48moodJBLU−0.58moodGNTX−0.11moodMED±19.2%earnings Oct 26HTH−0.39moodMRNA−0.62moodALV−0.08moodDEA±6.3%earnings Oct 26GMAB+0.53moodMBLY−0.62moodDASH−0.33moodHBT±5.5%earnings Oct 26FLG−0.48moodJBLU−0.58moodGNTX−0.11moodMED±19.2%earnings Oct 26HTH−0.39moodMRNA−0.62mood

HBT±5.5%earnings Oct 26FLG−0.48moodJBLU−0.58moodGNTX−0.11moodMED±19.2%earnings Oct 26HTH−0.39moodMRNA−0.62moodPURR+0.67moodMNSB±4.8%earnings Oct 26CORT−1.00moodSGML+0.46moodMAIN−0.65moodHBT±5.5%earnings Oct 26FLG−0.48moodJBLU−0.58moodGNTX−0.11moodMED±19.2%earnings Oct 26HTH−0.39moodMRNA−0.62moodPURR+0.67moodMNSB±4.8%earnings Oct 26CORT−1.00moodSGML+0.46moodMAIN−0.65mood

HTH−0.39moodMRNA−0.62moodPURR+0.67moodMNSB±4.8%earnings Oct 26CORT−1.00moodSGML+0.46moodMAIN−0.65moodABG±11.5%earnings Oct 27ELME−1.00moodCRDO−0.29moodCPIX−1.00moodACU±9.7%earnings Oct 27HTH−0.39moodMRNA−0.62moodPURR+0.67moodMNSB±4.8%earnings Oct 26CORT−1.00moodSGML+0.46moodMAIN−0.65moodABG±11.5%earnings Oct 27ELME−1.00moodCRDO−0.29moodCPIX−1.00moodACU±9.7%earnings Oct 27

SGML+0.46moodMAIN−0.65moodABG±11.5%earnings Oct 27ELME−1.00moodCRDO−0.29moodCPIX−1.00moodACU±9.7%earnings Oct 27DECK−0.24moodNCLH−0.47moodET+0.58moodAEYE±25.9%earnings Oct 27FHB−0.25moodSGML+0.46moodMAIN−0.65moodABG±11.5%earnings Oct 27ELME−1.00moodCRDO−0.29moodCPIX−1.00moodACU±9.7%earnings Oct 27DECK−0.24moodNCLH−0.47moodET+0.58moodAEYE±25.9%earnings Oct 27FHB−0.25mood

CPIX−1.00moodACU±9.7%earnings Oct 27DECK−0.24moodNCLH−0.47moodET+0.58moodAEYE±25.9%earnings Oct 27FHB−0.25moodTMUS−0.46moodSLM−0.24moodAGYS±17.9%earnings Oct 27ONC+0.67moodBMY−0.32moodCPIX−1.00moodACU±9.7%earnings Oct 27DECK−0.24moodNCLH−0.47moodET+0.58moodAEYE±25.9%earnings Oct 27FHB−0.25moodTMUS−0.46moodSLM−0.24moodAGYS±17.9%earnings Oct 27ONC+0.67moodBMY−0.32mood

AEYE±25.9%earnings Oct 27FHB−0.25moodTMUS−0.46moodSLM−0.24moodAGYS±17.9%earnings Oct 27ONC+0.67moodBMY−0.32moodIOVA+1.00moodAMKR±20.6%earnings Oct 27T−0.45moodWSFS+0.51moodRCI+0.22moodAEYE±25.9%earnings Oct 27FHB−0.25moodTMUS−0.46moodSLM−0.24moodAGYS±17.9%earnings Oct 27ONC+0.67moodBMY−0.32moodIOVA+1.00moodAMKR±20.6%earnings Oct 27T−0.45moodWSFS+0.51moodRCI+0.22mood

ONC+0.67moodBMY−0.32moodIOVA+1.00moodAMKR±20.6%earnings Oct 27T−0.45moodWSFS+0.51moodRCI+0.22moodARE±16.1%earnings Oct 27LEVI−1.00moodABR−0.33moodSNNUF−0.82moodATI±13.6%earnings Oct 27ONC+0.67moodBMY−0.32moodIOVA+1.00moodAMKR±20.6%earnings Oct 27T−0.45moodWSFS+0.51moodRCI+0.22moodARE±16.1%earnings Oct 27LEVI−1.00moodABR−0.33moodSNNUF−0.82moodATI±13.6%earnings Oct 27

OKYO

← Markets

OKYOOKYO Pharma Limited

Discussion

Nothing said here yet.

to join the conversation.

—

Tue, Oct 6
10:09 AMYahoo
OKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
OKYO Pharma’s CEO Robert Dempsey joined Steve Darling from Proactive to announce a major clinical development milestone, with the first patients enrolled in the company’s Phase 3 NEPTUNE trial evaluating urcosimod as a potential treatment for neuropathic…
7:00 AMstocktitan.net+1
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
OKYO Pharma Ltd (NASDAQ:OKYO) enrolled the first patients in its Phase 3 trial of urcosimod for neuropathic corneal pain, a chronic and often severe eye condition with no FDA-approved treatment, the company said on Tuesday.
Tue, Sep 29
7:00 AMglobenewswire.com
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
LONDON and NEW YORK, Sept.
Wed, Sep 9
7:00 AMstocktitan.net
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
Tue, Sep 8
7:00 AMglobenewswire.com
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
LONDON and NEW YORK, Sept.
Tue, Jul 28
7:00 AMYahoo
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases,…
Mon, Jul 27
7:00 AMYahoo
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.
Thu, Jul 23
12:00 PMYahoo
OKYO Pharma Announces Purchase of Shares by Director
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.
7:00 AMYahoo
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Executive Officer, Robert J.
Wed, Jul 22
12:00 PMYahoo
OKYO Pharma Announces Purchase of Shares by Chairman
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr.
10:00 AMYahoo
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S.
7:00 AMYahoo
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.